Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omacetaxine mepesuccinate - Teva Pharmaceutical Industries

X
Drug Profile

Omacetaxine mepesuccinate - Teva Pharmaceutical Industries

Alternative Names: C41443; Ceflatonin®; CGX-635; CXS-635; HHT; Homoharringtonine; Homoharringtonine-ChemGenex; NCI 141633; Omapro™; Synribo

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemGenex Pharmaceuticals; Stragen Pharma SA
  • Developer ChemGenex Pharmaceuticals; Roswell Park Cancer Institute; Teva Pharmaceutical Industries; University of Hong Kong; University of Texas M. D. Anderson Cancer Center
  • Class Alkaloids; Antineoplastics; Harringtonines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cyclin D1 inhibitors; MCL1 protein inhibitors; Protein synthesis inhibitors; Proto-oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies
  • Discontinued Acute promyelocytic leukaemia; Solid tumours

Most Recent Events

  • 21 Feb 2021 Omacetaxine mepesuccinate is still in phase II trials for Acute myeloid leukaemia in Hong Kong (NCT03135054) (NDR batch 18)
  • 10 Dec 2020 University of Hong Kong completes enrolment in a phase II trial in Acute myeloid leukaemia (Newly diagnosed, Second-line therapy or greater, Combination therapy) in HongKong (NCT03135054)
  • 14 Apr 2020 M.D. Anderson Cancer Center and Teva Pharmaceuticals completes the phase II trial in myelodysplastic syndrome in USA (SC) (NCT02159872)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top